NCT04764227View on ClinicalTrials.gov

Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 30, 2020

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2027

Conditions
Esophagus CancerEsophageal Squamous Cell CarcinomaChemoradiotherapyRadiation TherapyPostoperative
Interventions
DRUG

Paclitaxel

paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5

DRUG

Carboplatin

carboplatin AUC=2, ivgtt, d1, qw\*5

RADIATION

Radiotherapy

1.8Gy/d, d1-5/week, 28Fx

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER